What are you looking for:
Energy Sector News, Monday, July 28, 2025: Brent around $70, EU gas reserves near 70%, gasoline export ban
... spot market, bypassing American gas.
Concurrently, Europe continues its efforts to reduce dependence on Russian energy resources. The import of Russian oil and petroleum products into the EU has effectively ceased due to the existing embargo, while pipeline gas supplies have been reduced to minimal volumes. The European Union is actively developing infrastructure for LNG reception (new terminals are being constructed, and long-term contracts with alternative suppliers are being signed) to replace ...
Energy Sector News, Monday, August 4, 2025: Brent around $70 amid increased OPEC+ production, EU gas reserves exceed 70%, gasoline export ban in effect
... may lead to a realignment of global oil flows.
In Europe, the trend continues towards reducing dependence on Russian energy carriers. Imports of Russian oil and petroleum products into the EU have effectively ceased due to the existing embargo, and pipeline gas supplies have been reduced to minimal amounts. The EU is actively developing infrastructure for receiving LNG (new terminals are being built, and long-term contracts are being signed with alternative suppliers) to replace falling volumes....
Energy Sector News, Tuesday, August 5, 2025 - Trump Pressures India, Russia Limits Fuel Exports
... policy based on their economic interests.
In
Europe
, meanwhile, the course to reduce dependence on Russian energy carriers continues. Imports of Russian oil and petroleum products to the EU have been effectively halted by the existing embargo, and pipeline gas supplies have been reduced to minimal levels. The European Union is actively developing infrastructure for receiving LNG (new terminals are being built, and long-term contracts are being signed with alternative suppliers) to replace the volumes ...
Economic Events and Company Reports — Tuesday, July 29, 2025: Visa, Boeing, Spotify, and Others
... declines from COVID-19 products and withstand competition from generics. Investors will pay close attention to sales of the flagship immunotherapy, Keytruda, and the Gardasil vaccine. Also of focus will be comments about progress in new drug development (pipeline) that could help in future replenishments for expiring patent drugs. If financial results exceed forecasts (e.g., due to unexpectedly high vaccine or new drug sales) or the company raises its annual guidance, MRK shares may receive support. Conversely,...